Sofia Karkampouna

Rotterdam, ZH, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 36 publications

PU.1 is a mediator of the reactive stromal response associated with castration-resistant prostate cancer.

PU.1 is a mediator of the reactive stromal response associated with castration-resistant prostate cancer.

Journal: Communications biology

Published: July 21, 2025

Multi-layer stratified oncology platform utilizing transcriptomics, prostate cancer organoids, and modeling of drug response.

Multi-layer stratified oncology platform utilizing transcriptomics, prostate cancer organoids, and modeling of drug response.

Journal: Journal of experimental & clinical cancer research : CR

Published: May 21, 2025

Unraveling the YAP1-TGFβ1 axis: a key driver of androgen receptor loss in prostate cancer-associated fibroblasts.

Unraveling the YAP1-TGFβ1 axis: a key driver of androgen receptor loss in prostate cancer-associated fibroblasts.

Journal: Journal of experimental & clinical cancer research : CR

Published: May 11, 2025

Peptide-Modified Lipid Nanoparticles Boost the Antitumor Efficacy of RNA Therapeutics.

Peptide-Modified Lipid Nanoparticles Boost the Antitumor Efficacy of RNA Therapeutics.

Journal: ACS nano

Published: April 03, 2025

Cancer Organoids as reliable disease models to drive clinical development of novel therapies.

Cancer Organoids as reliable disease models to drive clinical development of novel therapies.

Journal: Journal of experimental & clinical cancer research : CR

Published: December 13, 2024

Influence of dosimetry accuracy on the correlation with treatment outcome in a preliminary PSMA radiopharmaceutical therapy study.

Influence of dosimetry accuracy on the correlation with treatment outcome in a preliminary PSMA radiopharmaceutical therapy study.

Journal: European journal of nuclear medicine and molecular imaging

Published: June 25, 2024

PSMA-PET follow-up to assess response in patients not receiving PSMA therapy: Is there value beyond localization of disease?

PSMA-PET follow-up to assess response in patients not receiving PSMA therapy: Is there value beyond localization of disease?

Journal: Theranostics

Published: March 28, 2024

Defining the challenges and opportunities for using patient-derived models in prostate cancer research.

Defining the challenges and opportunities for using patient-derived models in prostate cancer research.

Journal: The Prostate

Published: December 14, 2023

Accelerating histopathology workflows with generative AI-based virtually multiplexed tumour profiling.

Accelerating histopathology workflows with generative AI-based virtually multiplexed tumour profiling.

Journal: Nature machine intelligence

Published: December 04, 2023

Clinical sequencing identifies potential actionable alterations in a high rate of urachal and primary bladder adenocarcinomas.

Clinical sequencing identifies potential actionable alterations in a high rate of urachal and primary bladder adenocarcinomas.

Journal: Cancer medicine

Published: September 20, 2022

Bladder cancer organoids as a functional system to model different disease stages and therapy response.

Bladder cancer organoids as a functional system to model different disease stages and therapy response.

Journal: Nature communications

Published: June 14, 2022

Drug screening and genome editing in human pancreatic cancer organoids identifies drug-gene interactions and candidates for off-label treatment.

Drug screening and genome editing in human pancreatic cancer organoids identifies drug-gene interactions and candidates for off-label treatment.

Journal: Cell genomics

Published: February 21, 2022

Showing 1-12 of 36

Last Updated: 09/26/2026